EUVIMEDEUVIMED entdecken
Crossref

Integrated network pharmacology and therapeutic verification of Dendrobium officinale flower on primary dysmenorrhea via inhibition of the TLR4/NF-κB/COX-2 pathway

Manman Li, Pei Sheng, Weiqing Shi, Weiguang Li, Luqian Li, Xue Wang, Haixia Wu, Yuxin Wang, Xiaofei An, Lei Wang, Ming Yan

Fitoterapia · 2025

DOI: 10.1016/j.fitote.2025.106924 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fitoterapia, 2025. Verfasst von Manman Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China. Hauptthemen laut MEDLINE: Dysmenorrhea, Dendrobium, Plant Extracts. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dendrobium officinale flowers (DOF) offer a wide range of therapeutic benefits due to their rich content of bioactive compounds. Traditionally used in Chinese medicine, these flowers are valued for their health benefits, including anti-inflammatory and antioxidant properties, which may contribute to their therapeutic effects. The anti-inflammatory and antioxidant extract of DOF exhibited anti-primary dysmenorrhea (PD) activity in oxytocin-induced mice. This study aimed to unravel the underlying mechanisms of DOF-EA in treating PD using an integrative approach that combines network pharmacology and experimental verification. The active fraction, DOF-EA, was identified through anti-inflammatory and antioxidant activity assays. The phytochemical profile of DOF-EA was characterized by HPLC analysis. The therapeutic mechanisms of DOF-EA in treating PD were predicted using network pharmacology and molecular docking analyses. Moreover, the therapeutic effects of DOF-EA were confirmed using oxytocin-induced mice and uterine strip models. Enzyme activity assays and immunoblotting methods were employed for target validation. DOF-EA inhibited COX-2 with an IC50 of 0.44 μg/mL, scavenged DPPH radicals with an IC50 of 9.88 μg/mL, and suppressed NO production in RAW 264.7 cells with an IC50 of 8.08 μg/mL. Additionally, DOF-EA reduced the writhing response and decreased TNF-α and PGF2α levels in PD mice. It also inhibited contraction activity in uterine strips by blocking calcium channels. Furthermore, DOF-EA downregulated the expression of TLR4, NF-κB, COX-2, and p-IκBα, while upregulating the expression of HO-1 and Nrf2 in the uterine tissue of PD mice. In conclusion, DOF-EA exerts therapeutic effects against PD by inhibiting TLR4/NF-κB/COX-2 and promoting the Nrf2/HO-1 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DysmenorrheaDendrobiumPlant ExtractsAnimalsFemaleToll-Like Receptor 4MiceNF-kappa BCyclooxygenase 2FlowersAnti-Inflammatory AgentsNetwork PharmacologyMolecular Docking SimulationSignal TransductionAntioxidantsPhytochemicalsRAW 264.7 Cells

Stichwörter der Autor:innen

COX-2Dendrobium officinale flowersNF-κBNetwork pharmacologyPrimary dysmenorrheaTLR4

Substanzen

Toll-Like Receptor 4NF-kappa BTlr4 protein, mouseCyclooxygenase 2Anti-Inflammatory AgentsAntioxidantsPlant ExtractsPhytochemicalsPtgs2 protein, mouse

Autor:innen und Institutionen

  • School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China.
  • Department of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210009, Jiangsu Province, China.
  • Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, Jiangsu Province, China.
  • School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China.
  • New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China.
  • Department of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210009, Jiangsu Province, China. Electronic address: anxiaofei2000@163.com.

Zitieren

APA

Li, M., Sheng, P., Shi, W., Li, W., Li, L., Wang, X., Wu, H., Wang, Y., An, X., Wang, L., & Yan, M. (2025). Integrated network pharmacology and therapeutic verification of Dendrobium officinale flower on primary dysmenorrhea via inhibition of the TLR4/NF-κB/COX-2 pathway. Fitoterapia. https://doi.org/10.1016/j.fitote.2025.106924

Vancouver

Li M, Sheng P, Shi W, Li W, Li L, Wang X, et al. Integrated network pharmacology and therapeutic verification of Dendrobium officinale flower on primary dysmenorrhea via inhibition of the TLR4/NF-κB/COX-2 pathway. Fitoterapia. 2025. doi:10.1016/j.fitote.2025.106924

BibTeX
@article{Li2025,
  author = {Li, Manman and Sheng, Pei and Shi, Weiqing and Li, Weiguang and Li, Luqian and Wang, Xue and Wu, Haixia and Wang, Yuxin and An, Xiaofei and Wang, Lei and Yan, Ming},
  title = {Integrated network pharmacology and therapeutic verification of Dendrobium officinale flower on primary dysmenorrhea via inhibition of the TLR4/NF-κB/COX-2 pathway},
  journal = {Fitoterapia},
  year = {2025},
  doi = {10.1016/j.fitote.2025.106924}
}
Kostenlos starten →